Status:
UNKNOWN
Effects of Prostaglandin E1 Treatment on Pyloric Wall in Newborns
Lead Sponsor:
Hacettepe University
Conditions:
Pyloric Stenosis;Acquired
Congenital Heart Disease
Eligibility:
All Genders
Up to 28 years
Brief Summary
Prostaglandin E1 (PGE1) has been used in the medical treatment of ductal dependent critical congenital heart disease in neonates. Apnea/ bradycardia, hypotension, hypokalemia, feeding difficulties, fe...
Detailed Description
Intravenous prostaglandin E1 infusion is referred to as ductus dependent diseases, in systemic (aortic blood flow) circulation (eg critical aortic coarctation, intermittent arcus aorta, hypoplastic le...
Eligibility Criteria
Inclusion
- Newborn babies who are hospitalized in Hacettepe University Faculty of Medicine İhsan Doğramacı Children's Hospital Neonatal Intensive Care Unit and who are receiving prostaglandin E1 infusion due to PDA-dependent congenital heart disease.
- Newborns who have the above criteria and whose consent form has been enlightened by their parents has been read and accepted to participate in the study.
Exclusion
- Babies whose consent to participate in the study cannot be obtained.
- Babies with chromosomal disease or hereditary metabolic disease
- Babies who died during the first week of life and whose ultrasonography measurements could not be obtained.
Key Trial Info
Start Date :
May 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04496050
Start Date
May 6 2019
End Date
November 30 2020
Last Update
August 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hacettepe University
Ankara, Turkey (Türkiye)